menu
    • menu

    Company profile for HealthTech BioActives

    HealthTech BioActives-PSE
    News
    Global Leader Natural Solutions Through Responsible Management

    18 Dec 2025

    // PRESS RELEASE

    HTBA Spends €6 Million on New Factory in Spain

    10 Dec 2025

    // PRESS RELEASE

    HTBA Ranks in Top 5% of Sustainable Firms via EcoVadis

    06 Oct 2025

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    HealthTech Bioactives

    Contact Supplier

    Website

    BIO Partnering at JPM

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content

    https://www.youtube.com/embed/EUr0SrDqQ6I

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    Key Products KEY PRODUCTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    HealthTech BioActives, leading globally in Flavonoids and Vitamin B12 Derivatives.

    Related CompaniesRelated Companies

    About

    HTBA (HealthTech BioActives), a global company specialized in flavonoids and vitamin B12 derivatives, with over 40 years of experience in natural-origin pharmaceutical ingredients. We cover the entire value chain, from raw materials to merchandise, with global reach in pharmaceuticals, dietary supplements, human and animal nutrition, and in cosmetics. We recognize that our ingredients directly impact our customers’ activities and the well-being of end consumers. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    HealthTech BioActivesSpain_new Flag
    Country
    Country
    Spain
    Address
    Address
    Avinguda Diagonal, 567 4th Fl, Barcelona, Spain 08029
    Telephone
    Telephone
    +34 935044400
    Client Email
    Email
    showinfo@htba.com
    Client Website
    Website
    https://htba.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/healthtechbioactives/
    youtube
    YouTube
    http://www.youtube.com/@htbaformulatingnewstandard6257
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/healthtech-bioactives-party-content-4659.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/healthtech-bioactives-party-content-53267.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/healthtech-bioactives-party-content-66901.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions

    DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions

    Drug Master Files, or DMFs, are confidential documents that play a crucial role in the pharmaceutical industry. These files, submitted to the US Food and Drug Administration (FDA), contain detailed information about ingredients, manufacturing processes, and packaging of medicines. They help the FDA oversee drug quality. Of the four types, Type II DMFs involve active pharmaceutical ingredients (APIs) for both branded and generic drugs. The third quarter (Q3) of 2024 saw Type II DMF submissions set a new record. A total of 309 Type II DMFs were submitted to the FDA during this period, a substantial 24.6 percent increase over Q3 2023 (with 248 submissions). The second quarter of 2024 too saw a remarkable increase, with 237 Type II DMFs being submitted compared to 178 in Q2 2023. View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) China witnesses steep rise in DMF submissions, beats India with maximum filings In Q3 2024, China filed 153 DMFs submissions, marking a substantial 57.7 percent increase from the 97 submissions filed in Q3 2023. India maintained its strong position but fell to the number two spot with 110 DMFs, representing a modest 3.8 percent increase from 106 in Q3 2023. The US, which came a distant third, saw a slight decline in DMF submissions, with 13 filed in Q3 2024, as compared to 18 in Q3 2023. For several years, India had a lead in Type II DMFs. Since 2020, which marked the start of the pandemic, we have noticed a gradual increase in DMFs filed by China. This year, China has surpassed India considerably in the first three quarters. During the first nine months of 2024, China submitted 372, while India filed 286 DMFs. If this lead is maintained in Q4, DMFs from China will surpass that of India in 2024.  Amongst European countries, Spain led with seven DMFs, followed by Italy at four, and Germany and the Netherlands at three each. Among other nations, Japan contributed six while Israel submitted four DMFs. In company-wise tally, China’s Jiangsu East-Mab Biomedical Technology topped the list with an impressive 14 DMFs. On its heels were Indian companies — MSN at 13 DMFs, and Vamsi Labs and Hetero Drugs at nine DMFs each. China’s Porton Pharma and Wuxi AppTec filed five, while Shanghai Keze Yongxin Biotechnology, and Qingdao Glycogene Pharmaceutical contributed four submissions each. India's Maithri Drugs also submitted four. Japanese company Santeja filed five. Overall, Asia accounted for nearly 90 percent, with China contributing a dominant 49.5 percent of all DMF submissions. India was at 35.6 percent, the US at 4.2 percent, while Europe contributed 6.5 percent.  View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) Diabetes, obesity, cancer, women’s health drugs emerge as hot molecules in Q3 2024 In terms of molecules, semaglutide (used for the treatment of type 2 diabetes and weight management) and relugolix (to treat prostate cancer and uterine fibroids) saw six DMF filings each in Q3 2024, indicating significant industry interest in these compounds. Following closely behind were semaglutide’s competitor tirzepatide and overactive bladder therapy vibegron, garnering four DMFs each. Finerenone (a non-steroidal drug for chronic kidney disease associated with type 2 diabetes) and voclosporin (an immunosuppressant for lupus nephritis) saw three DMFs each.  The last quarter also witnessed the introduction of 14 molecules with first-time DMFs. Among them were acetoxy empagliflozin, cabozantinib fumarate, tivozanib hydrochloride monohydrate, diosmetin, trilaciclib, clenbuterol hydrochloride, fenoterol hydrobromide, tapinarof and fezolinetant. Fezolinetant, with a DMF from Spain’s Moehs Iberica, is the active ingredient in Astellas’ Veozah, which is the first non-hormonal treatment for menopausal symptoms approved by the FDA. Tapinarof, filed by India’s Maithri Drugs, is used in Vtama, a novel steroid-free psoriasis cream. Other compounds that made their DMF debut include berotralstat, calcium phosphoryl choline chloride, phloroglucinol dihydrate, belumosudil mesylate and trimethylphloroglucinol. During Q2 2024, there were 19 drugs that saw DMF submissions for the first time, including molecules like triptorelin, sorafenib, pralsetinib, trilaciclib dihydrochloride, resmetirom (hepatology) and teneligliptin hydrochloride hydrate (metabolic disorders).  View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available)    GDUFA fee for FY 2025: The FDA’s Generic Drug User Fee Amendments (GDUFA) is a law designed to speed access to safe and effective generic drugs to the public and reduce costs to the industry. The fiscal year 2025 fee rates were published on July 31, 2024. The FDA has revised fees under GDUFA III for all categories. While there is a slight increase in the DMF fee from US$ 94,682 in 2024 to US$ 95,084 in 2025, the ANDA fee has witnessed a significant jump — from US$ 252,453 in 2024 to US$ 321,920 in 2025. FY 2024 and FY 2025 User Fee Rates Generic drug fee category Fees rates for FY 2024 Fees rates for FY 2025 Applications: Abbreviated New Drug Application (ANDA) US$ 2,52,453   US$ 3,21,920   Drug Master File (DMF) US$ 94,682 US$ 95,084 Facilities: Active Pharmaceutical Ingredient (API)—Domestic US$ 40,464 US$ 41,580 API—Foreign US$ 55,464 US$ 56,580 Finished Dosage Form (FDF)—Domestic US$ 2,20,427   US$ 2,31,952 FDF—Foreign US$ 2,35,427   US$ 2,46,952 Contract Manufacturing Organization (CMO)—Domestic US$ 52,902 US$ 55,668 CMO—Foreign US$ 67,902 US$ 70,668 GDUFA Program: Large size operation generic drug applicant US$ 17,29,629   US$ 18,91,664 Medium size operation generic drug applicant US$ 6,91,852   US$ 7,56,666 Small business generic drug applicant US$ 1,72,963   US$ 1,89,166 Our view The highlight of the last few quarters has been the sharp rise in Type II DMF filings from China. The submission of a DMF is not required by law or any FDA regulation. FDA’s DMF guideline offers guidance on acceptable approaches to meeting regulatory requirements. Moreover, DMFs establish trust in APIs from lesser-known companies. With a growing emphasis on compliance and quality assurance, it appears that Chinese drug companies are eager to demonstrate their commitment to high standards and build trust in the US market. And that’s good news for the pharmaceutical industry.   
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 9330

    https://www.pharmacompass.com/radio-compass-blog/dmf-filings-hit-all-time-high-in-q3-2024-china-tops-list-with-58-increase-in-type-ii-submissions

    #PharmaFlow by PHARMACOMPASS
    24 Oct 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Global Leader Natural Solutions Through Responsible Management
    Global Leader Natural Solutions Through Responsible Management

    18 Dec 2025

    // PRESS RELEASE

    https://htba.com/global-leaders-in-natural-solutions-with-responsible-management-of-our-environmental-impact/

    PRESS RELEASE
    18 Dec 2025
    Share Share
    HTBA Spends €6 Million on New Factory in Spain
    HTBA Spends €6 Million on New Factory in Spain

    10 Dec 2025

    // PRESS RELEASE

    https://htba.com/htba-invests-over-6-million-euros-in-a-new-production-plant-at-its-industrial-center-in-spain/

    PRESS RELEASE
    10 Dec 2025
    Share Share
    HTBA Ranks in Top 5% of Sustainable Firms via EcoVadis
    HTBA Ranks in Top 5% of Sustainable Firms via EcoVadis

    06 Oct 2025

    // PRESS RELEASE

    https://htba.com/htba-renews-ecovadis-gold-medal-ranking-among-the-top-5of-most-sustainable-companies-evaluated-last-year/

    PRESS RELEASE
    06 Oct 2025
    Share Share
    HTBA Offsets Carbon via Social & Green Projects in Asia
    HTBA Offsets Carbon via Social & Green Projects in Asia

    29 Sep 2025

    // PRESS RELEASE

    https://htba.com/htba-offsets-carbon-footprint-with-social-and-environmental-projects-in-china-and-india/

    PRESS RELEASE
    29 Sep 2025
    Share Share
    HTBA Hosts Murcia Industrial Plan for Regional Growth
    HTBA Hosts Murcia Industrial Plan for Regional Growth

    25 Sep 2025

    // PRESS RELEASE

    https://htba.com/htba-hosts-the-presentation-of-the-industrial-plan-of-murcia-in-commitment-to-the-regions-economic-and-technological-development/

    PRESS RELEASE
    25 Sep 2025
    Share Share
    HTBA Launches Sugarex AQUA at EAS Congress 2025
    HTBA Launches Sugarex AQUA at EAS Congress 2025

    23 Sep 2025

    // PRESS RELEASE

    https://htba.com/sugarex-aqua-launch-at-the-2025-european-aquaculture-society-eas-congress/

    PRESS RELEASE
    23 Sep 2025
    Share Share

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Contact HealthTech BioActives and get a quotation

    HealthTech BioActives is a supplier offers 13 products (APIs, Excipients or Intermediates).

    Find a price of Diosmin bulk with DMF, CEP offered by HealthTech BioActives

    Find a price of Diosmetin bulk with DMF offered by HealthTech BioActives

    Find a price of Methylcobalamin bulk with JDMF offered by HealthTech BioActives

    Find a price of Cobamamide bulk offered by HealthTech BioActives

    Find a price of Hesperidin bulk offered by HealthTech BioActives

    Find a price of Hesperidin Methylchalcone bulk offered by HealthTech BioActives

    Find a price of Hydroxocobalamin bulk offered by HealthTech BioActives

    Find a price of Hydroxocobalamin Acetate bulk offered by HealthTech BioActives

    Find a price of Hydroxocobalamin Hydrochloride bulk offered by HealthTech BioActives

    Find a price of Neohesperidin bulk offered by HealthTech BioActives

    Find a price of Neohesperidin Dihydrochalcone bulk offered by HealthTech BioActives

    Find a price of Olive bulk offered by HealthTech BioActives

    Find a price of Quercetin bulk offered by HealthTech BioActives

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search